MX390320B - Farmaco de combinacion. - Google Patents

Farmaco de combinacion.

Info

Publication number
MX390320B
MX390320B MX2017009246A MX2017009246A MX390320B MX 390320 B MX390320 B MX 390320B MX 2017009246 A MX2017009246 A MX 2017009246A MX 2017009246 A MX2017009246 A MX 2017009246A MX 390320 B MX390320 B MX 390320B
Authority
MX
Mexico
Prior art keywords
combination drug
treating
relates
present
cancer
Prior art date
Application number
MX2017009246A
Other languages
English (en)
Other versions
MX2017009246A (es
Inventor
Hiroshi Sakamoto
Toshiyuki Tsukaguchi
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56405915&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX390320(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of MX2017009246A publication Critical patent/MX2017009246A/es
Publication of MX390320B publication Critical patent/MX390320B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente invención se relaciona a un fármaco que es para tratar o prevenir cáncer, que es efectivo en el tratamiento del cáncer, y que comprende una combinación de un inhibidor ALK y un inhibidor VEGF. La presente invención también se relaciona a un método para tratar o prevenir cáncer y un método para inhibir crecimiento tumoral.
MX2017009246A 2015-01-16 2016-01-15 Farmaco de combinacion. MX390320B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015007244 2015-01-16
PCT/JP2016/051067 WO2016114375A1 (ja) 2015-01-16 2016-01-15 併用医薬

Publications (2)

Publication Number Publication Date
MX2017009246A MX2017009246A (es) 2017-10-12
MX390320B true MX390320B (es) 2025-03-20

Family

ID=56405915

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017009246A MX390320B (es) 2015-01-16 2016-01-15 Farmaco de combinacion.

Country Status (13)

Country Link
US (2) US11077093B2 (es)
EP (1) EP3246047B1 (es)
JP (1) JP6741596B2 (es)
KR (1) KR102584344B1 (es)
CN (1) CN107249639B (es)
AU (1) AU2016207431B2 (es)
BR (1) BR112017013982A2 (es)
CA (1) CA2973857C (es)
IL (1) IL253400B (es)
MX (1) MX390320B (es)
RU (1) RU2740261C2 (es)
TW (1) TWI752901B (es)
WO (1) WO2016114375A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2942186C (en) 2014-06-18 2023-06-27 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising non-ionic surfactants
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
BR112018013407A2 (en) 2015-12-30 2018-12-18 Kodiak Sciences Inc. antibodies and conjugates thereof
IT201800001168A1 (it) * 2018-01-17 2019-07-17 Fond Per Listituto Oncologico Di Ricerca Ior Nuovi farmaci senolitici inibitori alk
SG11202008242XA (en) 2018-03-02 2020-09-29 Kodiak Sciences Inc Il-6 antibodies and fusion constructs and conjugates thereof
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
CN116261455B (zh) * 2020-09-25 2024-11-01 苏州亚盛药业有限公司 一种药物组合物及其在治疗癌症中的用途
CN118338913A (zh) * 2022-01-18 2024-07-12 齐鲁制药有限公司 螺环芳基磷氧化物与抗vegf抗体的药物组合
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0892090A (ja) 1994-07-26 1996-04-09 Tanabe Seiyaku Co Ltd 医薬組成物
ATE172463T1 (de) 1994-08-04 1998-11-15 Hoffmann La Roche Pyrrolocarbazol
EA001450B1 (ru) 1996-05-01 2001-04-23 Эли Лилли Энд Компани Галогензамещенные ингибиторы протеинкиназы с
US6632822B1 (en) 1999-05-14 2003-10-14 The Australian National University Compounds and therapeutic methods
GB0030417D0 (en) 2000-12-13 2001-01-24 Pharma Mar Sa An anticancer lead compound isolated from a New Zealand ascidian
FR2841138B1 (fr) 2002-06-25 2005-02-25 Cll Pharma Composition pharmaceutique solide contenant un principe actif lipophile, son procede de preparation
AU2004258801A1 (en) 2003-02-28 2005-02-03 Inotek Pharmaceuticals Corporation Tetracyclic Benzamide Derivatives and methods of use thereof
DE60305634T2 (de) 2003-03-07 2006-09-21 Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Anaplastisches Lymphoma Kinase Testverfahren, Reagenzien und Kompositionen davon
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
CA2532800C (en) 2003-07-23 2013-06-18 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
US7378414B2 (en) 2003-08-25 2008-05-27 Abbott Laboratories Anti-infective agents
PT1687305E (pt) 2003-11-21 2008-10-17 Novartis Ag Derivados de 1h-imidazoquinolina como inibidores de proteína quinase
CA2548600A1 (en) 2003-12-12 2005-06-23 Merck Frosst Canada & Co. Cathepsin cysteine protease inhibitors
JP4927704B2 (ja) 2004-03-19 2012-05-09 シュペーデル・エクスペリメンタ・アーゲー 有機化合物
CA2559866A1 (en) 2004-03-31 2005-10-20 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
BRPI0513915A (pt) 2004-08-26 2008-05-20 Pfizer compostos aminoeteroarila enantiomericamente puros como inibidores de proteìna quinase
US7091202B2 (en) 2004-09-15 2006-08-15 Bristol-Myers Squibb Company 4-arylspirocycloalkyl-2-aminopyrimidine carboxamide KCNQ potassium channel modulators
AU2006245421A1 (en) 2005-05-12 2006-11-16 Pfizer Inc. Anticancer combination therapy using sunitinib malate
GB0517329D0 (en) 2005-08-25 2005-10-05 Merck Sharp & Dohme Stimulation of neurogenesis
CA2626446A1 (en) 2005-11-07 2007-05-18 Irm Llc Compounds and compositions as ppar modulators
US7601716B2 (en) 2006-05-01 2009-10-13 Cephalon, Inc. Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
US8063225B2 (en) 2006-08-14 2011-11-22 Chembridge Corporation Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
EP2222647B1 (en) 2006-10-23 2015-08-05 Cephalon, Inc. Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors
JP2010524953A (ja) 2007-04-17 2010-07-22 ブリストル−マイヤーズ スクイブ カンパニー 縮合ヘテロ環１１−β−ヒドロキシステロイドデヒドロゲナーゼＩ型阻害剤
TWI389893B (zh) 2007-07-06 2013-03-21 Astellas Pharma Inc 二（芳胺基）芳基化合物
EA018503B1 (ru) 2007-07-20 2013-08-30 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Замещенные производные индазола, активные как ингибиторы киназы
EP2227233B1 (en) 2007-11-30 2013-02-13 Newlink Genetics Ido inhibitors
ES2510866T3 (es) 2008-03-13 2014-10-21 Daiichi Sankyo Company, Limited Mejora de la solubilidad de una preparación que contiene olmesartán medoxomilo
AU2010244218B2 (en) 2009-05-07 2012-07-19 Astrazeneca Ab Substituted 1-cyanoethylheterocyclylcarboxamide compounds 750
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
PL2975024T3 (pl) 2009-06-10 2018-09-28 Chugai Seiyaku Kabushiki Kaisha Związki tetracykliczne
GB0910046D0 (en) 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
BR112013003879B1 (pt) 2010-08-20 2020-12-22 Chugai Seiyaku Kabushiki Kaisha composição compreendendo compostos tetracíclicos e formulação oralmente administrável que a compreende
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
LT2822953T (lt) * 2012-03-06 2017-04-10 Pfizer Inc. Makrocikliniai dariniai, skirti proliferacinių ligų gydymui
TR201815994T4 (tr) 2012-09-25 2018-11-21 Chugai Pharmaceutical Co Ltd Ret inhibitörü.
CN106458967A (zh) 2014-04-25 2017-02-22 中外制药株式会社 四环化合物的新结晶
CN106456651A (zh) 2014-04-25 2017-02-22 中外制药株式会社 以高用量含有四环性化合物的制剂
US9428812B2 (en) * 2014-04-28 2016-08-30 Insight Genetics, Inc. Kit comprising primers for amplifying ALK kinase domain nucleic acids
CA2942186C (en) 2014-06-18 2023-06-27 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising non-ionic surfactants
TWI718102B (zh) 2014-08-08 2021-02-11 日商中外製藥股份有限公司 ４環性化合物的非晶質體

Also Published As

Publication number Publication date
US20180000779A1 (en) 2018-01-04
AU2016207431B2 (en) 2021-05-06
EP3246047A1 (en) 2017-11-22
CN107249639A (zh) 2017-10-13
RU2017128616A (ru) 2019-02-18
US11896579B2 (en) 2024-02-13
US20210322380A1 (en) 2021-10-21
RU2740261C2 (ru) 2021-01-12
KR20170104519A (ko) 2017-09-15
KR102584344B1 (ko) 2023-09-27
US11077093B2 (en) 2021-08-03
AU2016207431A1 (en) 2017-07-20
JPWO2016114375A1 (ja) 2017-10-19
MX2017009246A (es) 2017-10-12
TWI752901B (zh) 2022-01-21
IL253400A0 (en) 2017-09-28
CA2973857C (en) 2023-11-07
JP6741596B2 (ja) 2020-08-19
EP3246047C0 (en) 2024-12-25
RU2017128616A3 (es) 2019-07-17
EP3246047A4 (en) 2018-08-22
EP3246047B1 (en) 2024-12-25
IL253400B (en) 2022-03-01
BR112017013982A2 (pt) 2018-01-02
TW201632205A (zh) 2016-09-16
CN107249639B (zh) 2021-05-18
WO2016114375A1 (ja) 2016-07-21
CA2973857A1 (en) 2016-07-21

Similar Documents

Publication Publication Date Title
MX390320B (es) Farmaco de combinacion.
EA201591509A1 (ru) Ингибиторы cdc7
PH12016502179A1 (en) Inhibitors of lysine specific demethylase-1
ZA202000148B (en) Heterocyclic inhibitors of atr kinase
EA201891340A1 (ru) Лечение рака с использованием 2-дезокси-2-фтор-l-фукозы в комбинации с ингибитором контрольных точек
BR112019002331A2 (pt) anticorpos anti-siglec-7 para o tratamento do câncer e métodos para obtenção dos mesmos
EA201891057A1 (ru) Композиции и способы для ингибирования активности аргиназы
MX2017008844A (es) Terapia de combinacion con inhibidor de acetil-coa carboxilasa (acc) para el tratamiento de enfermedad de higado graso no alcoholico.
CY1121444T1 (el) Παραγωγα κιnoλonης ως αναστoλεις υποδοχεα αυξητικου παραγοντα ινοβλαστων
EA201790170A1 (ru) Терапевтические соединения-ингибиторы
DK3277842T3 (da) Fremgangsmåder til at behandle kræftpatienter med farnesyl-transferase-inhibitorer
BR112018011709A2 (pt) inibidores bicíclicos de pad4
EA201791736A1 (ru) Комбинированная терапия для лечения рака
EA201591278A1 (ru) Композиции, содержащие c1-inh, и способы профилактики и лечения расстройств, ассоциированых с дефицитом ингибитора с1 эстеразы
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
EA201792227A1 (ru) Лечение рака легких ингибиторами глутаминазы
EA201792496A1 (ru) Способы лечения воспаления или нейропатической боли
EA201791095A1 (ru) Способ лечения рака
MX382996B (es) Inhibidores de pcna
MX376201B (es) Compuestos inhibidores de metaloenzima.
EA201692472A1 (ru) Соединения для лечения рака мозга
MX2020006297A (es) Variantes de cd19.
MX2022012386A (es) Compuestos inhibidores de metaloenzimas.
MX382904B (es) Combinaciones de fármacos para tratar mieloma múltiple.
PH12017501879A1 (en) Methods for treating cancer